This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk13: Good afternoon and welcome to Oncolytics Biotech's fourth quarter and full year 2023 conference call. All participants are now in a listen-only mode. There will be a question and answer session at the end of this call. Please be advised that this call is being recorded at the company's request. I would now like to turn the conference call over to John Patton, Director of Investor Relations and Communication. Please go ahead.
spk09: Thank you, Operator, and good afternoon, everyone. Earlier today, Oncleric's issued a press release providing recent operational highlights and financial results for the fourth quarter and full year of 2023. A replay of today's call will be available on the events section of the Oncleric's website approximately two hours after its completion. After remarks from company management, we will open the call for Q&A. As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of Palo Rio Rep. including statements regarding the company's mission, strategy, and objectives, the company's belief as to the potential mechanism of action and benefits of Pellet Re-Rep as a cancer therapeutic, our clinical development plans for 2024, including initiation of our first registrational studies for Pellet Re-Rep, a manufacturing program, our cash runway, and other statements related to anticipated developments in the company's business. These statements are based on management's current expectations and beliefs and are subject to a number of factors, which involve known and non-risk delays, uncertainties, and other factors not under the company's control that may cause actual results, performance, or achievements of the company to be materially different from the results, performance, or expectations implied by these forward-looking statements. In any forward-looking statement in which Onclinix expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis. There can be no assurance that the statement, expectation, or belief will be achieved. These factors include results of current or pending clinical trials, risks associated with intellectual property production, financial projections, actions by regulatory agencies, and those factors detailed in the company's filings with CDAR and the SEC. Oncologics does not undertake any obligation to update these forward-looking statements except as required by applicable laws. The Oncologics Management Team is on the call today to review our fourth quarter 2023 and year-end results, including Chief Executive Officer, Dr. Matt Coffey, Chief Financial Officer, Kirk Look, Chief Medical Officer, Dr. Tom Heinemann, and Vice President, Product Development, Allison Hagerman. Now, I will turn the call over to Dr. Coffey. Matt.
spk04: Thank you, John. Good afternoon, and welcome to the Oncolytics Biotech fourth quarter conference call. 2024 marks the year that Oncolytics will become a late-stage cancer company. with the initiation of our first registrational studies for our proprietary immunotherapeutic product candidate, Pella-RioRep, or Pella, as we'll refer to it. This brings us closer to achieving our mission of improving the lives of patients with cancer, so we'll begin the year with significant enthusiasm. The transition to becoming a late-stage biopharma company reflects significant progress in positive clinical and translational data reported from our clinical programs in 2023. A key element of this transition is making smart investments in manufacturing, which is why Allison Hagerman will join us to talk about the steps we're taking so Oncolytics is set up for success as Pelham is closer to beginning registrational trials. During our call today, we would like to share some of the key highlights from the last several months, outline our clinical and strategic objectives for 2024, including the manufacturing, review our financial results for the fourth quarter and full year 2023, and take your questions. Positive clinical and translational data helped close 2023 on a high note. Starting with our clinical results, we reported positive clinical data from three cohorts in the Phase 1-2 goblet study in pancreatic cancer, colorectal cancer, and anal cancer. Each indication has achieved the predefined quote-unquote stage 1 success criteria, defined according to the Simon 2-stage study design. Data from the pancreatic and anal cancer cohorts demonstrated response rates that were nearly three times greater than published historical controls. Positive clinical results were supported by valuable translational data from further analysis of the AWARE-1 breast cancer study and from cohorts in the Goblet study. These data underscore Pella's mechanism of action as an immunotherapeutic agent. Importantly, the data demonstrated a positive correlation between response rates and PELL's ability to induce the expansion of T cell populations, measured by increases in the cell TIL score and the level of tumor infiltrating lymphocytes, or TILs, in the peripheral blood. TIL expansion could become an important biomarker of clinical outcomes that could be used in future clinical studies and to guide patient care. The positive data that we reported throughout 2023 include the Bracelet-1 breast cancer data reported in June, have also attracted interest and enhanced ongoing interactions with our clinical collaborators and potential strategic partners. The overall survival data for bracelet 1 continues to mature for patients receiving Pella and Paclitaxel. Overall survival is an important metric to potential partners and will likely serve as a catalyst to further our ongoing business development conversations. Additionally, these conversations have further informed our thinking on the design of future registrational studies. We've sharpened our strategic thinking thanks to the contributions of our board of directors, including our new director, Pat Andrews. Her experience in navigating registrational trials in oncology and completing transformational business development agreements complements and expands the strategic expertise of our board. We look to extend the transformational and strategic mindset in all of our discussions in 2024 and beyond. Now, as we look ahead, we are steadfast in our focus on achieving important objectives this year that move Pella forward on the regulatory pathway. These include, in the first half of the year, we intend to provide guidance on a registrational path for Pella in breast cancer. Also in 2024, we plan to initiate a registration study for Pella in pancreatic cancer using an adaptive design. I'd like to take a moment to expand on our thinking for each indication, starting with breast cancer. We expect our registrational strategy in breast cancer to focus on an evaluation of Pella in combination with Paxlitaxel compared to Paxlitaxel monotherapy in patients with metastatic disease who are HR positive, HER2 negative. As a reminder, we are continuing to follow patients in the bracelet one, HR positive, HER2 negative metastatic breast cancer study and expect to report overall survival data this year. That being said, The data we've reported so far are supportive of the statistically significant near doubling of median overall survival seen in the IND213 study. With respect to our plans for pancreatic cancer, we expect our registration study to focus on the evaluation of Pella in combination with apetalizumab, gemcitabine, and nabpaclitaxel compared to the combination of gemcitabine and nabpaclitaxel in patients receiving first-line treatment for pancreatic ductal adenocarcinoma, or PDAC. We continue to develop a study protocol that utilizes an adaptive design, building on the positive results from the goblet study. The registrational strategy for PDAC will incorporate learnings from our previous interactions with the Pancreatic Cancer Action Network, also known as PANCAN, and ongoing conversations with their newly announced alliance partner, the Global Coalition for Adaptive Research, or GCAR. As a result of these relationships, we've been able to collaborate with key opinion leaders in the pancreatic cancer community and their enthusiasm propels potential, and this indication reinforces our commitment to bringing new treatment options to patients. I'd also like to mention the expansion of the enrollment in the Goblet cohort focused on anal cancer. The American Cancer Society estimates that there will be about 10,500 new cases of this cancer in 2024. We recently announced plans to begin enrolling stage two of this cohort based on positive results in the first stage of the Simon two-stage program. reported at an international medical meeting in November of last year. The study will evaluate the combination of Pella and atezolizumab in patients with second-line or later disease. While inner cancer is very rare, there is no standard of care for these patients who have progressed to advanced disease, so positive results may provide an opportunity for a rapid regulatory pathway. We hope to report additional data in 2025. Before I turn the call over to Tom Heinemann, there are three key messages we would like you to take away from today's call. First and foremost, propelled by the encouraging clinical and translational data we unveiled in 2023, Pella is poised to embark on registrational trials for pancreatic cancer and breast cancer as early as 2024. The consistently positive outcomes from seminal studies such as BRACELET-1, AWARE-1, and GOBLET have captured the attention and deepening engagement of the clinical oncology community and potential strategic partners. Secondly, we eagerly anticipate the forthcoming release of overall survival data from the Bracelet-1 breast cancer study in 2024. This data represents an important milestone anticipated to serve as a significant catalyst in bolstering our registration endeavors for Pella and a focal point of interest for our prospective biopharma collaborators. Lastly, the compelling data stemming from the anal carcinoma cohort of the Goblet study advocates for the expansion of this cohort. With the potential for fewer than 20 additional patients to be enrolled, we could swiftly transition towards a registrational study in this critical unmet need area. Particularly noteworthy is the distinctive approach of excluding chemotherapy in favor of leveraging the demonstrated synergy between Pella and a checkpoint inhibitor, underscoring our commitment to pioneering novel and effective treatment modalities. Finally, as always, I'd like to thank everyone in the Oncolytics organization and our collaborators for your dedication to the mission to improve the care of patients with cancer. Your work to advance the development of Pella inspires me and everyone around us every day.
spk06: Tom? Thanks, Matt. During today's call, I'd like to provide a snapshot of the key features of Pella and an update on our ongoing clinical programs. Pella is administered intravenously, which allows it to work systemically by selectively infecting tumor cells wherever they may be in the patient. Some tumor cells are killed directly by Pella infection. In other cases, Pella infection results in the accumulation of double-stranded RNA in the cancer cells. This induces a pro-inflammatory response in the tumor microenvironment that primes the tumor for immunologic killing. Specifically, Pella infection results in increased T-cell infiltration into the tumor, expansion of tumor infiltrating lymphocytes, also known as TILs, and stimulation of both innate and adaptive immune responses. We can assess the immunotherapeutic action of Pella through clinical effects such as changes in tumor size, time to disease progression, and overall survival. In addition, we can assess the immunologic effects of Pella treatment by such measures as the expansion of kills in the blood. Data demonstrating a positive correlation between clinical response and till expansion support the potential use of this measure as a biomarker in future clinical trials and during patient care. In 2023, Oncolytics provided important clinical and translational data from the BRACE1 study, from multiple Goblet study cohorts, and from the AWARE1 study. Based on these results, I will take you through our clinical plan for 2024. As Matt indicated, this year we expect to provide guidance on a registrational plan for Pella and breast cancer, initiate a registrational study of Pella and pancreatic cancer, and report the overall survival results from the Bracelet-1 breast cancer study. In addition, we plan to initiate a new pancreatic cancer cohort in the Goblet study. The new cohort will evaluate Pella plus modified Fulfirodox with or without a Tizolizumab in patients with newly diagnosed metastatic pancreatic cancer. This new cohort will be supported by the $5 million Pan-Can Therapeutic Accelerator grant and has been submitted to the German regulatory authorities. We also will expand enrollment into the anal carcinoma arm of the GOBLEP study. Now I'd like to add a few additional comments on the BRACEL1 breast cancer data, the new pancreatic cancer cohort in the GOBLEP study, and the expansion of the GOBLEP study anal carcinoma cohort. We continue to follow BRACEL1 study patients for survival. The last patient enrolled in the study will reach two years of follow-up in 2024. Once this milestone is reached, the survival results will be analyzed and we will expect to report these results by the end of the year. As Matt mentioned, we also expect to provide an update on our registrational plans for breast cancer in the first half of this year. The progression-free survival results already reported from Bracelet 1 are consistent with the near doubling of median overall survival seen in the earlier IND213 breast cancer study. Furthermore, they support the possible use of progression-free survival as the primary endpoint in a future registrational breast cancer study, which would reduce the time required to complete the primary study analysis. Moving to the GOBLIP study, the new pancreatic cancer cohort, in which we will evaluate the combination of Pella plus modified fulfirinox with or without atezolizumab, is expected to begin enrollment in the coming months. We are enthusiastic about this new cohort because it will enable us to study Pella in combination with one of the most widely used pancreatic cancer treatment backbones and to directly assess the value of adding a checkpoint inhibitor. We are very grateful and encouraged by the support we received from PANCAN to conduct this study. PANCAN is an important voice in the pancreatic cancer community, and our work with them has led to valuable relationships with key leaders in this field Moreover, their belief in the potential of Pella provides additional validation of our efforts in this indication. Positive results from this study could expand the population of pancreatic cancer patients who may benefit from Pella-based therapy and may ultimately provide physicians with much needed treatment options for this devastating disease. We expect to begin enrollment into this study cohort in the coming months. Before closing, I'd like to talk about the enrollment expansion of the Goblet Anal Carcinoma cohort, in which patients are being treated with a combination of Pella and atezolizumab and without any chemotherapy. In November of 2023, we reported encouraging preliminary results from this cohort, namely a 37.5% objective response rate compared to historical results for checkpoint inhibitors alone of 10 to 14%. Based on this, we have decided to expand enrollment into this cohort by additional 18 valuable patients, and we plan to add more study sites to reduce the enrollment time. We believe potential biopharma partners have a keen interest in this cohort because of the limited benefit provided by checkpoint inhibitor monotherapy, which is commonly used in second-line or later anal carcinoma patients. Furthermore, the promising preliminary results from this cohort support Pella's ability to synergize with checkpoint inhibitors and enhance their efficacy in cancers where they've historically provided little benefit. This study could open the door to an additional registrational pathway for Pella and an indication with a clear medical need. Finally, I would like to express our appreciation to the patients, study site staff, and investigators who participated in our clinical studies. We are very grateful to you for making these research efforts possible. As you can tell, 2024 will be a year rich in clinical activities, and I look forward to updating you on our progress as the year unfolds. Next up, as Matt mentioned at the start of the call, Allison will provide an update on our manufacturing and product development efforts. Allison?
spk08: Thanks, Tom. I'm excited to share the progress we've made over these past few months. As Matt and Tom have just shared, 2024 is poised to be a very important year for Oncolytics as we advance Pella to registrational study readiness. A key element of this advance is the cornerstone investment we will be making in the Pella product supply. Throughout my discussion, you will hear me use the word product, product supply, and supply chain. These are all industry terms related to manufacturing and are not intended to denote an FDA-approved product. I will also use the term drug substance meaning purified bulk Pella-Riorette material, the active pharmaceutical ingredient. Drug substance is used in the manufacture of drug products, the finished dosage form packaged for patient administration. Key takeaways from my section are we have a well-established product supply chain for Pella. We have made numerous batches of material at increasing scale, and Pella has a long shelf life. We have been working with a high-quality contract manufacturing organization for some time. and we are investing in optimized manufacturing scale-up and validation so that we are ready to support product registration. For a bit of background, Pella drug substance is produced in a simple eight-step process and stored in bulk at minus 80 degrees Celsius. Finished drug product can be stored at minus 80 or minus 20 degrees Celsius. Pella material has a long shelf life. With ongoing drug substance stability out past 10 years, plus an established drug product expiration period of six years from date of product filling. Pella is made by our Contract Development and Manufacturing Organization, or CDMO, Millipore Sigma SAFC, located in the San Diego area. Master and working cell banks and virus banks are established and validated. All raw materials are sourced from qualified suppliers, and the process operating parameters are well defined. We have been working with this organization, formerly known as Sigma Aldrich, for more than 15 years with consistent staffing at both organizations. The Millipore Sigma site has a well-established quality management system, and our protocols and procedures are well aligned. In addition, the site produces GMP materials for other organizations, including commercial products, and has completed nine successful inspections, including the FDA and other health authorities. They have handled numerous biologics over the years and are a leader in biovector manufacturing, so they are familiar with assets like Pella. Stable staffing, a well-established quality management system, and working with a CDMO that has been FDA inspected are all very important for consistency, quality, and risk management, which are always top of mind in manufacturing. In the fourth quarter of 2023, we initiated a new GMP production campaign with the drug substance process transition to single-use equipment and scaled up to a 200-liter bioreactor, increasing the purified batch size to about 12 liters of bulk drug substance. The first GMP batch has been completed, and once routine manufacture has been established, our next step will be the validation batches. Our successful track record in scale-up and consistent production gives us confidence that our investment in the next level of Pella drug substance batches will go well as we continue this work in 2024 and 2025. In conjunction with the scale-up, we also optimized some upstream elements of the process, including a change in detergent to align with European long-term guidelines. Thankfully, this switch won't impact the purified drug substance or products. The detergents is cleared through the purification steps, and the final teleproduct concentration and formulation remains the same. In addition to drug substance manufacture, in the fourth quarter of 2023, we also completed a second automated drug product fill in a full isolator system. This provides an aseptic environment for filling and high level of sterility assurance, and also allows for larger quantities per lot, reducing the cost of goods. Moving on to a few operational notes, Pella is very simple to ship and store at study sites. We believe a user-friendly product interface is important and are confident that Pella fits that specification well. Pella drug product single-dose vials are shipped to study sites on dry ice and can be stored at minus 80 or in a minus 20 Celsius freezer. It is straightforward to prepare a dose for administration to patients. From where we stand today, we have an adequate supply in place to support our current and future clinical program, including the registration-enabled studies. In conclusion, Oncolytics has invested very carefully in our supply chain so that we can support our clinical program and be ready to validate commercial manufacturing processes at the right time in support of future product registration. We plan to invest in manufacturing over the next year to support our registration plans for Pella. Once we close our prepared remarks, I will be happy to take questions, and I look forward to providing further manufacturer updates over the course of the year. Now, I'd like to turn the call over to Kirk to review the financial results for the last year. Kirk?
spk02: Thanks, Alison, and good afternoon, everyone. In this segment of the call, I'd like to take you through our financial results. I will be providing data in Canadian dollars unless otherwise noted. Full summary of our financial results can be found on the investor section of our website under filings and reports or in the press release issued earlier this afternoon. The company closed the year with $34.9 million in cash and cash equivalents compared to $32 million in cash, cash equivalents and marketable securities as of December 31, 2022. We believe this will enable us to achieve the most critical near-term milestones set out in today's call. The net loss for the fourth quarter of 2023 was $3.9 million compared to $8.6 million in the fourth quarter of 2022, equating to a net loss of $0.05 per share in the fourth quarter of 2023 compared to $0.14 a share for the same period of 2022. The net loss for the full year of 2023 was $27.8 million compared to $24.8 million in the full year 2022. equating to a net loss of 41 cents per share for the 23 period and a net loss of 43 cents per share for the 2022 period on a consolidated basis. The net loss for the fourth quarter and full year of 2023 included gains of $4.8 million and $5.3 million, respectively, mainly related to the change in fair value of warrants issued as part of our 2023 public offerings. General and administrative expenses for the fourth quarter of 2023 were 4.2 million compared to 3.7 million for the fourth quarter of 2022. For the full year of 2023, general and administrative expenses were 16.1 million compared to 11.5 million for the full year of 2023. The changes between the fourth quarter and full year of 2023 and the respective 2022 periods were mainly due to higher investor relations activities. Our full year 2023 expenses also included a portion of our 2023 public offering transaction costs. Now research and development expenses for the fourth quarter of 2023 were 4.7 million compared to $4.8 million for the fourth quarter of 2022. For the full year 2023, research and development expenses were 17.7 million compared to 15.4 for the full year 2022. The changes between the fourth quarter and full year 2023 and the respective 2022 periods were driven by higher manufacturing expenses associated with implementing single-use equipment and scaling up our drug substance production process. This is offset by lower costs related to our ongoing clinical studies and reduced clinical and safety data management. Now, in closing, I'd like to spend a moment to elaborate on a few of Matt's comments regarding our organizational transitions. Pella is a potential backbone immunotherapy that has shown efficacy signals in multiple indications. We have meaningful data from over 120 metastatic HR-positive HER2-negative breast cancer patients and 120 pancreatic cancer patients. Notably, we continue to capitalize on opportunities to further validate Pella's potential through initiatives like PANCAN's therapeutic accelerator program, which after a thorough and highly competitive process resulted in the grant of $5 million fully funding our modified Fulfironox PDAC cohort in Goblet. There are also opportunities to broaden Pella's application to indications like anal cancer, where an efficacy signal has emerged. We have assembled a management team that is well-positioned to bring Pella to patients, and attracting a board member like Pat Andrews reflects the strength of our team and Pella's potential. Finally, we have fostered important relationships with organizations like PanCan, Precog, AIO, and clinical collaborators like Pfizer and Roche. Our positive clinical data is enriching our discussion with a number of current and potential clinical and strategic partners. Before I turn the call back to Matt, I'd like to note that our financial strategy and organizational development have provided us with a cash runway through critical clinical milestones and into 2025. I look forward to providing you with further updates on our transformation to a late-stage oncology company throughout the year. Matt?
spk04: Thanks, Kirk. The clinical data we reported in 2023 put Pella on a clear trajectory towards registration, with metastatic breast cancer and metastatic pancreatic cancer as our highest priority indications. Our dedication to collaboration and engagement remains steadfast as we foster important discussions with the clinical oncology community and prospective strategic partners. Together, we are committed to expediting Pella's journey to markets, ensuring both swift progress and financial prudence every step of the way. This collective effort fuels our optimism and drives us towards a future where Pella's transformative potential can positively impact countless lives. As we conclude today's call and embark on this new year, we have a bright outlook for the development of Pella and a hopeful outlook for patients with an unwavering dedication to our mission. Together, all of us, we're pioneering a path filled with hope, determination, and the resolute belief that every step forward brings us closer to uplifting patients' lives and the reshaping landscape of cancer treatment. We look forward to updating you on our progress this year, and thank you for taking the time with us today. Operator, I would now like to open the call for questions.
spk13: Thank you. Ladies and gentlemen, we will now conduct a question and answer session. If you have a question, please press star followed by the number one on your touchstone phone. You will hear a three-tone prompt acknowledging your request. If you would like to cancel your request, please press star two. Please ensure you lift the handset before pressing any keys. Your first question comes from the line of Sumit Roy from Jones Research. Your line is now open.
spk14: Good afternoon, everyone, and thank you again for all the details on the progress, especially on the manufacturing front. A quick question on the... Breast cancer trial, trying to understand if you expect any change in the basic baseline patient characteristics, your breast test trial versus the potential pivotal trial in terms of part two status or companion treatments, any differences you expect. And also on the manufacturing front, As you have fairly clearly explained, there is a good transfer of technology between prior and current manufacturing. If the release criteria isn't everything, anything that could change the viral characteristics, any color would be appreciated.
spk06: Yeah, sure. Tom Heinemann here. I can speak to the first part of your question on the breast cancer study. The population will be very similar to the bracelet study population, there will be some differences due to the evolving standard of care in the target population, in particular the approval recently of antibody drug conjugates, but it will be largely similar to the bracelet population in that it will be in patients who have failed hormonal therapy, HR positive for two negative breast cancer patients who have failed hormonal therapy and who are now ready for their next stage of their treatment.
spk05: And maybe I'll let Allison Hagerman speak to the next part of your question.
spk07: Thanks, Tom. With regard to the question related to technology transfer and any change in virus characteristics, no, there are no changes to the virus characteristics of the B products. Either the drug substance or the product, the raw material input remain the same, including the master and working virus stocks. And all product batches are tested, including identity testing, potency, purity, and virus concentration to assure comparability and suitability for clinical use.
spk00: Thank you. Thank you again for taking the question. Your next question comes from the line of John Newman from Canaccord.
spk13: Your line is now open.
spk10: Hi, guys. Thank you for taking my question. I just wondered if you could talk a little bit more about the design of the pivotal study in pancreatic cancer, including the potential endpoints that you could look at there. Thanks.
spk00: Hey, John. It's Matt Coffey.
spk04: What we're looking at is very similar to what we initially had planned with the PanCan people. It's quite an innovative design in the sense that it uses adaptive, and what we really thought was clever about it is it's an FTA-approved protocol, so they're used to the idea of an interim look and an adaptive study. It allows us to more expediently get to an approval. Obviously, PANC is a tough indication, so it lets us have an interim look as well to make sure that we're on the right track. Very similar to what you'd expect from the PANC and looking at that, the primary endpoint would be overall survival, which is most meaningful in this patient population. And obviously, in this patient population, it's an endpoint that we don't have to wait a very long time to get to, so it's attractive. from that perspective in the sense that it can get us to approval much earlier. So very similar to what we had historically done, we'd be looking basically to piggyback on a successful study design.
spk00: Okay, great. Thank you. Your next question comes from the line of Patrick Trucchio from HC Wainwright. Your line is now open.
spk12: Hi, everyone. This is Luis Santos in for Patrick. Just wanted to discuss a little bit more the expansion of the NO cohorts and if the planned number of patients was about 20, perhaps that was going to be sufficient to match the efficacy signals observed to date. And what is the approximate timing for that enrollment. Thank you.
spk06: Yeah, sure. Tom Heinemann again. So for the anal carcinoma cohort, the expansion will actually be 18 additional evaluable patients for a total of 28 evaluable patients, so 18 on top of the 10 in stage one of the study. And we, of course, have worked with our statistician to determine appropriate success criteria to establish or to confirm a signal in that population. So what we're looking for in that population would be, for a successful study, would be seven or more responses out of the 28 valuable patients. And that would provide, I think, a great deal of confidence that the treatment we're evaluating is active at a level higher than what is seen with the standard of care checkpoint inhibitor alone. And then once we confirm that signal, then we can discuss about next steps and how to move forward as rapidly as possible in that patient population.
spk00: Thank you.
spk06: Did that answer your question or was there additional questions? Okay, thank you.
spk12: I was going to ask a little bit about the timing for enrollment of that. Oh, the timing.
spk06: Yeah, I'm sorry. Yes, the study has been submitted. This study is a new cohort in the ongoing goblet study, which is being conducted in Germany with the AIO study group, which is a group of very, well respected and expert KOLs, you know, PIs in Germany. But because it is in Germany, the protocol has been submitted to the German regulatory authorities for their approval. We're not expecting any issues with that, and so we're hoping that enrollment will be able to start into that arm of the study probably sometime in May, but it will depend a little bit on the regulatory,
spk05: timelines of the German authorities.
spk00: Great. Thank you. Your next question comes from the line of Luis Chen from Cantor.
spk13: Your line is now open.
spk11: Hi. Good afternoon, everyone. This is Kari from Cantor. Thank you for taking our questions. On your OS data guidance of Bracelet 1 study this year, given the data presented so far, can you help us frame expectations here, how it might change the treatment paradigm? Our second question is on OPEX. Given your clinical activities, can you talk about the push and pulls on OPEX for 2024?
spk00: Thank you. Harvey, we missed the second part of your question about OPEX. Yes, we'd just like to know the push and pulls on OpEx for 2024, given your studies ongoing. For whatever reason, we have a terrible connection. Yeah, it's breaking up. Sorry.
spk11: Oh, yeah, maybe we can – okay. Is this better or still the same? Yeah. Okay. We'd like to know the push and pulls on OpEx for 2024.
spk00: Any color there?
spk06: So Tom Heinemann here, I cannot address the second part, but I can address the first part about the overall survival results. In the bracelet study per protocol, the study will end two years after the last patient was enrolled. So that will be late in the second quarter. And when that occurs, then we will be in a position to do the final database cleaning and the final calculations around the overall survival. So we expect to have overall survival results in the, probably in the third quarter, internally in the third quarter, but this will be reported later in the year.
spk05: Does that answer your question related to the overall survival?
spk11: And given your hazard ratio that was provided earlier, that was last year, what are the expectations here, you know, given the population? How many months are we thinking of? Any, how it might change the treatment paradigm? Any information would be helpful. Thank you.
spk06: Well, as we reported last year, the progression-free survival showed a 50 to 100% benefit compared to the control arm in the bracelet study, okay? And so, we, I don't want to speculate on the overall survival results until we have all the data and have opportunity to review it appropriately per protocol. But we are optimistic that the overall survival will ultimately be in line with the, and by I say be in line, I don't mean necessarily month for month, but that the overall survival will ultimately validate the PFS benefit that we saw and reported nine months ago or so.
spk00: Awesome. That's great.
spk11: I don't know if the rest of the management team was able to hear my second question, but if not, that's all right too.
spk03: Thank you. Yeah, Noah, just what were you wanting to know about our operating costs?
spk11: Yes. So, you know, you guys have ongoing studies and institutional report, but also initiating coming up with an initially new study. So I just want to know how we should think about OpEx for this year.
spk03: Okay.
spk02: So for 2024, just compared to 23, we do see those coming off in terms of our operating costs more in line with, I guess, 2022's, sorry, 2021's level on the OpEx. In terms of the R&D and clinical-related costs, it'll just be a function of how quickly we can move forward with our clinical plan, moving the pancreatic cancer program forward and into the clinic, and then what we hear from the FDA on the breast cancer study.
spk00: Got it. Thank you so much. We have run out of time for additional questions.
spk13: I will now hand the call over to Dr. Matt Coffey for closing remarks.
spk04: Once again, I would like to thank everyone for making time to hear about our recent programs and how we're planning to evolve into a late-stage oncology company this year. The data supporting COLA as a novel immunotherapeutic agent with the ability to improve patient outcome continues to grow, and we're setting the stage to add to that this year. I look forward to our next update, and I wish everyone a wonderful evening. Thank you.
spk13: Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.
Disclaimer